Weiss Multi Strategy Advisers LLC cut its position in shares of Eli Lilly and Company (NYSE:LLY) by 0.2% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 6,126 shares of the company’s stock after selling 12 shares during the period. Weiss Multi Strategy Advisers LLC’s holdings in Eli Lilly and were worth $515,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. First Command Financial Services Inc. boosted its stake in shares of Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock worth $103,000 after buying an additional 84 shares during the period. Heritage Trust Co bought a new position in Eli Lilly and during the first quarter worth $135,000. Penserra Capital Management LLC raised its position in Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock worth $170,000 after buying an additional 176 shares in the last quarter. Crestwood Advisors Group LLC bought a new position in Eli Lilly and during the first quarter worth $179,000. Finally, Sandy Spring Bank raised its position in Eli Lilly and by 51.8% in the first quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock worth $185,000 after buying an additional 750 shares in the last quarter. 75.61% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company (NYSE:LLY) traded down 0.61% during midday trading on Thursday, hitting $82.07. The stock had a trading volume of 366,427 shares. Eli Lilly and Company has a 1-year low of $64.18 and a 1-year high of $86.72. The stock’s 50-day moving average is $83.02 and its 200-day moving average is $81.68. The company has a market capitalization of $86.58 billion, a PE ratio of 35.51 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.86 earnings per share. Equities research analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be paid a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.52%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s payout ratio is currently 90.04%.

ILLEGAL ACTIVITY NOTICE: This article was originally published by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/weiss-multi-strategy-advisers-llc-cuts-position-in-eli-lilly-and-company-lly/1470812.html.

A number of research analysts have recently weighed in on the company. Berenberg Bank restated a “buy” rating and issued a $98.00 target price on shares of Eli Lilly and in a report on Friday, August 4th. BMO Capital Markets restated a “sell” rating and issued a $73.00 target price on shares of Eli Lilly and in a report on Friday, August 4th. TheStreet upgraded Eli Lilly and from a “c+” rating to a “b+” rating in a report on Tuesday, July 25th. UBS AG lowered Eli Lilly and to a “hold” rating and set a $85.00 target price on the stock. in a report on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. lowered Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 target price on the stock. in a report on Wednesday, July 26th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the stock. Eli Lilly and currently has an average rating of “Hold” and an average price target of $88.27.

In other news, insider Melissa S. Barnes sold 1,900 shares of Eli Lilly and stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $80.78, for a total transaction of $153,482.00. Following the completion of the sale, the insider now owns 14,041 shares of the company’s stock, valued at $1,134,231.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Michael J. Harrington sold 22,833 shares of Eli Lilly and stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $79.97, for a total transaction of $1,825,955.01. Following the sale, the vice president now directly owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. In the last three months, insiders sold 669,733 shares of company stock valued at $55,845,287. 0.20% of the stock is owned by insiders.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.